XT
VINC

XTX Topco’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

XTX Topco’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-916
Closed -$13.1K – 3088
2024
Q3 		$13.1K Buy
916
+7
+0.8% +$96 ﹤0.01% 1894
2024
Q2 		$14.7K Buy
+909
New +$22.8K ﹤0.01% 1651
2023
Q4 		– Sell
-842
Closed -$17.4K – 2259
2023
Q3 		$17.4K Buy
+842
New +$16.3K ﹤0.01% 1387

Other funds holding VINC

SRC
Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

XTX Topco's VINC Position: Q4 2024 in Review

XTX Topco sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q4 2024, closing a stake of 916 shares — an estimated $13.1K sold.

XTX Topco first reported a position in VINC in Q3 2023 and held it in 3 quarters. The position peaked at $17.4K in Q3 2023. 22 funds tracked by Wall St. Rank hold VINC as of Q4 2024.

  • XTX Topco reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • XTX Topco sold 916 Vincerx Pharma, Inc. Common Stock shares in Q4 2024, an estimated $13.1K.
  • XTX Topco first reported a position in Vincerx Pharma, Inc. Common Stock in Q3 2023 and held it in 3 quarters.
  • XTX Topco's Vincerx Pharma, Inc. Common Stock position peaked at $17.4K in Q3 2023.
  • 22 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q4 2024.

Based on XTX Topco's 13F filing for Q4 2024, filed 13 Feb 2025.